Keyphrases
Anti-PD-1
100%
Anti-PD-1 Immunotherapy
20%
Anti-programmed Cell Death Protein 1
20%
Antitumor T Cells
20%
CD103
20%
CD8+ T Cells
40%
CD8+ Tumor-infiltrating Lymphocytes
40%
Clonal Replacement
20%
Cytotoxic Activity
100%
Definitive Therapy
20%
Head-and-neck Cancer
100%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
40%
Locally Advanced
20%
Neoadjuvant
100%
Non-responders
20%
Pathological Response
40%
Pathological Tumor Response
20%
PD-1 Blockade
40%
Pembrolizumab
20%
Phase II Trial
20%
Post-neoadjuvant
20%
Postneoadjuvant Therapy
20%
Pre-surgical
20%
Programmed Death-ligand 1 (PD-L1)
40%
Resident T Cells
100%
Response Mechanism
20%
Single-cell Analysis
20%
Tissue-resident Memory
20%
Tumor
100%
Tumor Antigen
20%
Tumor Biopsy
20%
Tumor Microenvironment
60%
Tumor-infiltrating Lymphocytes
40%
Tumor-specific
20%
Two-dose
20%
Viable Tumor
20%
Medicine and Dentistry
CD8 Antigen
50%
Cytotoxic T-Cell
50%
Head and Neck Cancer
100%
Head and Neck Squamous Cell Carcinoma
50%
Immunotherapy
25%
Neoadjuvant Therapy
25%
Neoplasm
100%
Pembrolizumab
25%
Programmed Death 1 Receptor
25%
Recurrent Disease
25%
Specific Tumor
25%
T Cell
100%
Tumor Antigen
25%
Tumor Biopsy
25%
Tumor Infiltrating Lymphocyte
100%
Tumor Microenvironment
75%
Immunology and Microbiology
CD8
50%
Cytotoxic T-Cell
50%
Dynamics
25%
Immunotherapy
25%
Neck
100%
Pembrolizumab
25%
Programmed Death 1 Receptor
25%
Single Cell Analysis
25%
Squamous Cell
50%
T Cell
100%
Tumor Antigen
25%
Tumor-Infiltrating Lymphocytes
100%